HEADER TRANSFERASE 24-MAR-03 1OUK TITLE THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE TITLE 2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: MITOGEN-ACTIVATED PROTEIN KINASE 14; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: MITOGEN-ACTIVATED PROTEIN KINASE P38, MAP KINASE P38, COMPND 5 CYTOKINE SUPPRESSIVE ANTI-INFLAMMATORY DRUG BINDING PROTEIN, CSAID COMPND 6 BINDING PROTEIN, CSBP, MAX-INTERACTING PROTEIN 2, MAP KINASE MXI2; COMPND 7 EC: 2.7.1.37; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: MAPK14; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET KEYWDS MAP KINASE, HYDROPHOBIC POCKET, KINASE DOMAIN, ATP BINDING DOMAIN, KEYWDS 2 TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR C.E.FITZGERALD,S.B.PATEL,J.W.BECKER,P.M.CAMERON,D.ZALLER, AUTHOR 2 V.B.PIKOUNIS,S.J.O'KEEFE,G.SCAPIN REVDAT 4 16-AUG-23 1OUK 1 REMARK SEQADV REVDAT 3 11-OCT-17 1OUK 1 REMARK REVDAT 2 24-FEB-09 1OUK 1 VERSN REVDAT 1 02-SEP-03 1OUK 0 JRNL AUTH C.E.FITZGERALD,S.B.PATEL,J.W.BECKER,P.M.CAMERON,D.ZALLER, JRNL AUTH 2 V.B.PIKOUNIS,S.J.O'KEEFE,G.SCAPIN JRNL TITL STRUCTURAL BASIS FOR P38ALPHA MAP KINASE QUINAZOLINONE AND JRNL TITL 2 PYRIDOL-PYRIMIDINE INHIBITOR SPECIFICITY JRNL REF NAT.STRUCT.BIOL. V. 10 764 2003 JRNL REFN ISSN 1072-8368 JRNL PMID 12897767 JRNL DOI 10.1038/NSB949 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH N.J.LIVERTON,J.W.BUTCHER,C.F.CLAIBORNE,D.A.CLAREMON, REMARK 1 AUTH 2 B.E.LIBBY,K.T.NGUYEN,S.M.PITZENBERGER,H.G.SELNICK,G.R.SMITH, REMARK 1 AUTH 3 A.TEBBEN,J.P.VACCA,S.L.VARGA,L.AGARWAL,K.DANCHECK, REMARK 1 AUTH 4 A.J.FORSYTH,D.S.FLETCHER,B.FRANTZ,W.A.HANLON,C.F.HARPER, REMARK 1 AUTH 5 S.J.HOFSESS,M.KOSTURA,J.LIN,S.LUELL,E.A.O'NEILL,S.J.O'KEEFE REMARK 1 TITL DESIGN AND SYNTHESIS OF POTENT, SELECTIVE, AND ORALLY REMARK 1 TITL 2 BIOAVAILABLE TETRASUBSTITUTED IMIDAZOLE INHIBITORS OF P38 REMARK 1 TITL 3 MITOGEN-ACTIVATED PROTEIN KINASE REMARK 1 REF J.MED.CHEM. V. 42 2180 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM9805236 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.8 REMARK 3 NUMBER OF REFLECTIONS : 18239 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM; 5% DATA FLAGGED REMARK 3 R VALUE (WORKING SET) : 0.213 REMARK 3 FREE R VALUE : 0.264 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 870 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.60 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.80 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.3050 REMARK 3 BIN FREE R VALUE : 0.3640 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 84 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2804 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 42 REMARK 3 SOLVENT ATOMS : 138 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 42.20 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 41.60 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 13.49800 REMARK 3 B22 (A**2) : 0.00000 REMARK 3 B33 (A**2) : 0.00000 REMARK 3 B12 (A**2) : 1.26300 REMARK 3 B13 (A**2) : -14.76000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.32 REMARK 3 ESD FROM SIGMAA (A) : 0.38 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.42 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.47 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.012 REMARK 3 BOND ANGLES (DEGREES) : 1.430 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.20 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.920 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : ANISOTROPIC REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : MASK REMARK 3 KSOL : 0.31 REMARK 3 BSOL : 34.34 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: AS IMPLEMENTED IN CNX REMARK 4 REMARK 4 1OUK COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 25-MAR-03. REMARK 100 THE DEPOSITION ID IS D_1000018678. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 08-JUN-00 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : X-GEN REMARK 200 DATA SCALING SOFTWARE : X-GEN REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 18247 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 35.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 200 DATA REDUNDANCY : 5.800 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.10200 REMARK 200 FOR THE DATA SET : 8.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.60 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.7 REMARK 200 DATA REDUNDANCY IN SHELL : 5.70 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.37800 REMARK 200 FOR SHELL : 1.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: 1WFC REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 59.24 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.02 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SODIUM CITRATE, AMMUNIUM SULFATE, REMARK 280 HEPES BUFFER, PH 7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE REMARK 280 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 22.85100 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 63.02350 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 44.01900 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 63.02350 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 22.85100 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 44.01900 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -5 REMARK 465 SER A -4 REMARK 465 HIS A -3 REMARK 465 MET A -2 REMARK 465 LEU A -1 REMARK 465 GLU A 0 REMARK 465 MET A 1 REMARK 465 SER A 2 REMARK 465 GLN A 3 REMARK 465 PRO A 352 REMARK 465 LEU A 353 REMARK 465 ASP A 354 REMARK 465 GLN A 355 REMARK 465 GLU A 356 REMARK 465 GLU A 357 REMARK 465 MET A 358 REMARK 465 GLU A 359 REMARK 465 SER A 360 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 173 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLN A 11 135.37 172.14 REMARK 500 ASN A 14 57.90 31.04 REMARK 500 SER A 32 152.12 175.03 REMARK 500 ASN A 100 -17.34 -161.89 REMARK 500 ARG A 149 -14.69 81.29 REMARK 500 ASP A 150 49.51 -146.27 REMARK 500 ASP A 168 79.23 71.71 REMARK 500 ASP A 227 -178.34 -174.34 REMARK 500 SER A 252 98.56 -49.72 REMARK 500 GLN A 260 6.91 -58.04 REMARK 500 ASP A 313 99.35 -167.42 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 084 A 501 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1M7Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A REMARK 900 DIHYDROQUINAZOLINONE INHIBITOR DBREF 1OUK A 1 360 UNP Q16539 MK14_HUMAN 1 360 SEQADV 1OUK GLY A -5 UNP Q16539 CLONING ARTIFACT SEQADV 1OUK SER A -4 UNP Q16539 CLONING ARTIFACT SEQADV 1OUK HIS A -3 UNP Q16539 CLONING ARTIFACT SEQADV 1OUK MET A -2 UNP Q16539 CLONING ARTIFACT SEQADV 1OUK LEU A -1 UNP Q16539 CLONING ARTIFACT SEQADV 1OUK GLU A 0 UNP Q16539 CLONING ARTIFACT SEQRES 1 A 366 GLY SER HIS MET LEU GLU MET SER GLN GLU ARG PRO THR SEQRES 2 A 366 PHE TYR ARG GLN GLU LEU ASN LYS THR ILE TRP GLU VAL SEQRES 3 A 366 PRO GLU ARG TYR GLN ASN LEU SER PRO VAL GLY SER GLY SEQRES 4 A 366 ALA TYR GLY SER VAL CYS ALA ALA PHE ASP THR LYS THR SEQRES 5 A 366 GLY LEU ARG VAL ALA VAL LYS LYS LEU SER ARG PRO PHE SEQRES 6 A 366 GLN SER ILE ILE HIS ALA LYS ARG THR TYR ARG GLU LEU SEQRES 7 A 366 ARG LEU LEU LYS HIS MET LYS HIS GLU ASN VAL ILE GLY SEQRES 8 A 366 LEU LEU ASP VAL PHE THR PRO ALA ARG SER LEU GLU GLU SEQRES 9 A 366 PHE ASN ASP VAL TYR LEU VAL THR HIS LEU MET GLY ALA SEQRES 10 A 366 ASP LEU ASN ASN ILE VAL LYS CYS GLN LYS LEU THR ASP SEQRES 11 A 366 ASP HIS VAL GLN PHE LEU ILE TYR GLN ILE LEU ARG GLY SEQRES 12 A 366 LEU LYS TYR ILE HIS SER ALA ASP ILE ILE HIS ARG ASP SEQRES 13 A 366 LEU LYS PRO SER ASN LEU ALA VAL ASN GLU ASP CYS GLU SEQRES 14 A 366 LEU LYS ILE LEU ASP PHE GLY LEU ALA ARG HIS THR ASP SEQRES 15 A 366 ASP GLU MET THR GLY TYR VAL ALA THR ARG TRP TYR ARG SEQRES 16 A 366 ALA PRO GLU ILE MET LEU ASN TRP MET HIS TYR ASN GLN SEQRES 17 A 366 THR VAL ASP ILE TRP SER VAL GLY CYS ILE MET ALA GLU SEQRES 18 A 366 LEU LEU THR GLY ARG THR LEU PHE PRO GLY THR ASP HIS SEQRES 19 A 366 ILE ASP GLN LEU LYS LEU ILE LEU ARG LEU VAL GLY THR SEQRES 20 A 366 PRO GLY ALA GLU LEU LEU LYS LYS ILE SER SER GLU SER SEQRES 21 A 366 ALA ARG ASN TYR ILE GLN SER LEU THR GLN MET PRO LYS SEQRES 22 A 366 MET ASN PHE ALA ASN VAL PHE ILE GLY ALA ASN PRO LEU SEQRES 23 A 366 ALA VAL ASP LEU LEU GLU LYS MET LEU VAL LEU ASP SER SEQRES 24 A 366 ASP LYS ARG ILE THR ALA ALA GLN ALA LEU ALA HIS ALA SEQRES 25 A 366 TYR PHE ALA GLN TYR HIS ASP PRO ASP ASP GLU PRO VAL SEQRES 26 A 366 ALA ASP PRO TYR ASP GLN SER PHE GLU SER ARG ASP LEU SEQRES 27 A 366 LEU ILE ASP GLU TRP LYS SER LEU THR TYR ASP GLU VAL SEQRES 28 A 366 ILE SER PHE VAL PRO PRO PRO LEU ASP GLN GLU GLU MET SEQRES 29 A 366 GLU SER HET SO4 A 502 5 HET 084 A 501 37 HETNAM SO4 SULFATE ION HETNAM 084 4-[5-[2-(1-PHENYL-ETHYLAMINO)-PYRIMIDIN-4-YL]-1-METHYL- HETNAM 2 084 4-(3-TRIFLUOROMETHYLPHENYL)-1H-IMIDAZOL-2-YL]- HETNAM 3 084 PIPERIDINE FORMUL 2 SO4 O4 S 2- FORMUL 3 084 C28 H29 F3 N6 FORMUL 4 HOH *138(H2 O) HELIX 1 1 SER A 61 MET A 78 1 18 HELIX 2 2 LEU A 113 LYS A 118 1 6 HELIX 3 3 THR A 123 SER A 143 1 21 HELIX 4 4 LYS A 152 SER A 154 5 3 HELIX 5 5 ASP A 176 THR A 180 5 5 HELIX 6 6 VAL A 183 TYR A 188 1 6 HELIX 7 7 ALA A 190 LEU A 195 1 6 HELIX 8 8 THR A 203 GLY A 219 1 17 HELIX 9 9 ASP A 227 GLY A 240 1 14 HELIX 10 10 GLY A 243 ILE A 250 1 8 HELIX 11 11 SER A 252 GLN A 260 1 9 HELIX 12 12 ASN A 269 VAL A 273 5 5 HELIX 13 13 ASN A 278 LEU A 289 1 12 HELIX 14 14 THR A 298 ALA A 304 1 7 HELIX 15 15 HIS A 305 ALA A 309 5 5 HELIX 16 16 ASP A 313 GLU A 317 5 5 HELIX 17 17 GLN A 325 ARG A 330 5 6 HELIX 18 18 LEU A 333 SER A 347 1 15 SHEET 1 A 2 PHE A 8 LEU A 13 0 SHEET 2 A 2 THR A 16 PRO A 21 -1 O THR A 16 N LEU A 13 SHEET 1 B 5 TYR A 24 PRO A 29 0 SHEET 2 B 5 GLY A 36 ASP A 43 -1 O PHE A 42 N GLN A 25 SHEET 3 B 5 LEU A 48 LEU A 55 -1 O VAL A 52 N CYS A 39 SHEET 4 B 5 TYR A 103 HIS A 107 -1 O LEU A 104 N LYS A 53 SHEET 5 B 5 ASP A 88 PHE A 90 -1 N ASP A 88 O VAL A 105 SHEET 1 C 3 ALA A 111 ASP A 112 0 SHEET 2 C 3 LEU A 156 VAL A 158 -1 O VAL A 158 N ALA A 111 SHEET 3 C 3 LEU A 164 ILE A 166 -1 O LYS A 165 N ALA A 157 SITE 1 AC1 6 TYR A 69 ARG A 220 THR A 221 HOH A 677 SITE 2 AC1 6 HOH A 682 HOH A 700 SITE 1 AC2 14 TYR A 35 VAL A 38 ALA A 51 LYS A 53 SITE 2 AC2 14 GLU A 71 LEU A 75 ILE A 84 LEU A 104 SITE 3 AC2 14 THR A 106 HIS A 107 LEU A 108 MET A 109 SITE 4 AC2 14 ALA A 111 ASP A 168 CRYST1 45.702 88.038 126.047 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021881 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011359 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007934 0.00000